Spero Therapeutics (SPRO) Total Non-Current Liabilities (2016 - 2022)

Spero Therapeutics (SPRO) has 7 years of Total Non-Current Liabilities data on file, last reported at $48.9 million in Q4 2022.

• Quarterly Total Non-Current Liabilities fell 40.39% year-over-year to $48.9 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $48.9 million (down 40.39% YoY) and the FY2022 annual result came in at $48.9 million, down 40.39% from the prior year.
• Total Non-Current Liabilities advanced to $48.9 million in Q4 2022, from $32.0 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $82.4 million in Q1 2022 to a low of $5.9 million in Q1 2018.
• A 5-year average of $29.2 million and a median of $19.3 million in 2019 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2018 — Total Non-Current Liabilities surged 3450.5% — and 2022, when it sank 40.39%.
• Tracing SPRO's Total Non-Current Liabilities over 5 years: stood at $12.9 million in 2018, then jumped by 49.1% to $19.3 million in 2019, then soared by 41.46% to $27.3 million in 2020, then jumped by 200.66% to $82.0 million in 2021, then slumped by 40.39% to $48.9 million in 2022.
• The last three Total Non-Current Liabilities figures came in at $48.9 million (Q4 2022), $32.0 million (Q3 2022), and $27.7 million (Q2 2022), per Business Quant data.